Remicade infliximab: Phase III data; sBLA under review; marketed to reduce the signs and symptoms of RA and to treat Crohns disease

X-ray data from 348 patients in Centocor’s Phase III ATTRACT trial showed no median progression of joint damage from baseline in patients treated with Remicade in combination with methotrexate for 1 y...